CHECK OUT OUR
Laverock Therapeutics announces the appointment of Ali Elsley as Finance Director. Laverock has also significantly grown its team to 24 people, representing growth of 50% over the past year.
Laverock Therapeutics secures Innovate UK award to advance immune effector cell therapeutics programme using GEiGS® technology
Laverock Therapeutics raises £13.5M to develop unique gene silencing platform for programmable advanced therapies
Laverock Therapeutics founded to develop the next generation of programmable cell therapies
To find out more about our technology and discuss partnering opportunities, please get in touch.
© 2024 Laverock Therapeutics - All rights reserved • Terms and Conditions • Privacy Policy